Fluid overload in children with pediatric acute respiratory distress syndrome: A retrospective cohort study

Esther H Leow1, Judith J-M Wong2,3, Yee H Mok2

  • 1Department of Paediatric Nephrology, KK Women's and Children's Hospital, Singapore.

Pediatric Pulmonology
|October 11, 2021
PubMed

Insights

Fluid overload in pediatric acute respiratory syndrome (PARDS) is linked to higher mortality. The rate of fluid overload accumulation within 14 days impacts survival, while peak fluid overload affects recovery metrics.

Area of Science:

  • Pediatric Critical Care Medicine
  • Respiratory Medicine
  • Nephrology

Background:

  • Pediatric Acute Respiratory Syndrome (PARDS) is a critical illness with significant morbidity and mortality.
  • Fluid overload (FO) is a common complication in critically ill children, but its long-term impact in PARDS is not fully understood.
  • Understanding the relationship between FO and outcomes is crucial for optimizing patient management.

Purpose of the Study:

  • To investigate the association between cumulative fluid overload (CFO) up to 14 days post-PARDS diagnosis and pediatric intensive care unit (PICU) mortality.
  • To evaluate the impact of CFO on 28-day mechanical ventilation-free days (VFD) and 28-day intensive care unit-free days (IFD).
  • To determine if the rate of fluid accumulation influences patient outcomes.

Main Methods:

  • Retrospective cohort study of 165 PARDS patients admitted to the PICU between 2009 and 2015.
  • Daily FO calculated as (intake-output)/weight at PICU admission; Peak Cumulative FO (CFO) determined up to Day 14.
  • Logistic and linear regression models used to analyze associations with mortality, VFD, and IFD, adjusting for covariates like Pediatric Index of Mortality 2 score, PARDS severity, and acute kidney injury (AKI).

Main Results:

  • The study included 165 patients with a 45.5% mortality rate.
  • Acute kidney injury (AKI) and a higher rate to peak cumulative FO were significantly associated with increased mortality (aOR 3.19 and aOR 1.23, respectively).
  • Peak cumulative FO was associated with decreased VFD and IFD.

Conclusions:

  • The rate of CFO accumulation within the first 14 days of PARDS is a significant predictor of mortality.
  • Peak CFO is independently associated with poorer outcomes, including reduced VFD and IFD.
  • These findings underscore the importance of monitoring and managing fluid balance in pediatric patients with PARDS.
Abstract

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
441
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
278
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
236
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
390
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
421
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
2.0K